Search
Eterna Therapeutics Inc
ERNAAdd to Watchlist
3.850USD
-0.110-2.78%
Market hours 09/22, 11:00（ET）
4.50MMarket Cap
LossP/E TTM
Eterna Therapeutics Inc (ERNA) Stock Price Target & Forecast
Analyst Rating
Based on 1 analysts giving stock ratings to Eterna Therapeutics Inc in the past month.
Buy
0 Strong Buy
1 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
30.000USD+683.29%
ERNA Analyst Recommendation Trends
In the current month, ERNA has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ERNA average Analyst price target in the last month is 30.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
0
0
0
0
ERNA Analyst Rating for Peer Comparison
Updated: Sep 21, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
7
7
1
1
21
Financial Forecasting
Based on analysts' estimates, ERNA EPS is projected to reach -3.840 in FY2026Q3, following reported EPS of -3.396 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
--
--
-3.30
-3.84
-4.76
Actual
-0.18
-173.80
-3.40
--
--
Surprise
--
--
-2.90%
--
--
FAQs
What is Eterna Therapeutics Inc's price target?
Analysts forecast that Eterna Therapeutics Inc's price target is USD 30.00, with the highest forecast at USD 30.00 and the lowest forecast at USD 30.00.
What is the analyst rating for Eterna Therapeutics Inc?
Based on the ratings of Eterna Therapeutics Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.